We present data on whether memantine, an adamantane derivative and medical NMDA-receptor antagonist, improves spatial and latent learning deficits in amyloid precursor protein/presenilin 2 double-transgenic mice (PS2Tg2576 mice). PS2Tg2576 mice were subjected to Morris water maze (MWM) test for spatial memory and the water-finding test for latent memory testing at ages 3 and 5-6 months. At 3 months of age, the learning performance of PS2Tg2576 mice was normal compared to wild-type mice in both tasks. At 5-6 months of age, cognitive deficits were observed in the MWM and water-finding test; 2-3 weeks of memantine treatment (30 mg/kg/day, p.o.) significantly reverted the learning deficits in the MWM; however, had little effect on those in the...
<p>A) Neurological examination did not reveal any significant difference among groups. B) There was ...
Mentor: John Csernansky From the Washington University Undergraduate Research Digest: WUURD, Volume ...
Evaluation of the efficacy of novel therapeutics for potential treatment of Alzheimer's disease (AD)...
We present data on whether memantine, an adamantane derivative and medical NMDA-receptor antagonist...
We herein present behavioral data on whether memantine, an adamantane derivative and medical NMDA-re...
Memantine, a low- to moderate-affinity uncompetitive N-meth-yl-D-aspartate receptor antagonist, has ...
Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to improve learning an...
Ts65Dn (TS) mice exhibit several phenotypic characteristics of human Down syndrome, including an inc...
Abstract Background Memantine, a low- to moderate-affinity uncompetitive N-methyl-D-aspartate recept...
Background and Objective: Memantine (MEM) an uncompetitive N-methyl-D-aspartate receptor antagonist ...
Memantine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, and is an app...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder clinically characterized by imp...
Background and Purpose: N-methyl-D-aspartate (NMDA)-mediated neurotoxicity and oxidative stress have...
Folic acid deficiency and hyperhomocysteinemia potentiate amyloid-beta (A beta) neuron toxicity. Mem...
Memory loss is one of the key features of cognitive impairment in either aging, Mild Cognitive Impai...
<p>A) Neurological examination did not reveal any significant difference among groups. B) There was ...
Mentor: John Csernansky From the Washington University Undergraduate Research Digest: WUURD, Volume ...
Evaluation of the efficacy of novel therapeutics for potential treatment of Alzheimer's disease (AD)...
We present data on whether memantine, an adamantane derivative and medical NMDA-receptor antagonist...
We herein present behavioral data on whether memantine, an adamantane derivative and medical NMDA-re...
Memantine, a low- to moderate-affinity uncompetitive N-meth-yl-D-aspartate receptor antagonist, has ...
Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to improve learning an...
Ts65Dn (TS) mice exhibit several phenotypic characteristics of human Down syndrome, including an inc...
Abstract Background Memantine, a low- to moderate-affinity uncompetitive N-methyl-D-aspartate recept...
Background and Objective: Memantine (MEM) an uncompetitive N-methyl-D-aspartate receptor antagonist ...
Memantine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, and is an app...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder clinically characterized by imp...
Background and Purpose: N-methyl-D-aspartate (NMDA)-mediated neurotoxicity and oxidative stress have...
Folic acid deficiency and hyperhomocysteinemia potentiate amyloid-beta (A beta) neuron toxicity. Mem...
Memory loss is one of the key features of cognitive impairment in either aging, Mild Cognitive Impai...
<p>A) Neurological examination did not reveal any significant difference among groups. B) There was ...
Mentor: John Csernansky From the Washington University Undergraduate Research Digest: WUURD, Volume ...
Evaluation of the efficacy of novel therapeutics for potential treatment of Alzheimer's disease (AD)...